This week in managed care, the top stories included House Republicans' new plan to repeal and replace the Affordable Care Act, new funding from HHS to help small practices follow the Medicare Access and CHIP Reauthorization Act, and the Supreme Court rules on a patent lawsuit that impacts pharmaceutical companies.
Hello, I’m Justin Gallagher, associate publisher of The American Journal of Managed Care. Welcome to This Week in Managed Care from the Managed Markets News Network
House GOP Health Plan
Republicans in the House of Representatives this week unveiled their plan to repeal and replace the Affordable Care Act, a move that Speaker Paul Ryan said shows what healthcare could look like if voters elect a Republican president.
The biggest change in the GOP plan calls for ending the requirement that everyone have health insurance, an element that helps hold down the cost of coverage for older, sicker Americans by balancing their costs with those who are younger and use less healthcare services. The House GOP plan would also phase out the federal government’s support for Medicaid expansion, raise the Medicare eligibility age to 67, and use tax cuts and health savings accounts to make coverage more available and portable to those who cannot obtain it through their job.
The policy outline did not include cost estimates or projections of how many Americans would remain insured, but a separate action by the Obama Administration suggests getting young adults to enroll is already challenging, even with the individual mandate:
Stepping Up ACA Outreach
The Department of Health and Human Services plans to step up its outreach to those under the age of 35. Those who start an account on HealthCare.gov but do not enroll will receive emails reminding them of increased penalties under Obamacare if they do not obtain coverage.
Erica Hutchins Coe, a partner in the Center for US Health System Reform at McKinsey and Company, told AJMC recently that while more young adults have health coverage than did before the ACA, the GOP observation that the law has created narrow networks is valid. Watch the interview.
Patent Rule
The US Supreme Court has upheld a new process for challenging patents that the pharmaceutical industry opposed, and some believe this ruling could boost the number of generic drugs and push down prices.
A new US Patent Office regulation makes it more likely that patents could be overturned, which could make it harder for pharmaceutical companies to keep information away from generic manufacturers.
Marilyn Tavenner, president and CEO of America’s Health Insurance Plans, and Chip Davis of the Generic Pharmaceutical Association, praised the ruling: “Today’s decision from the Supreme Court is a significant win for consumers. By protecting and reaffirming the importance of the inter partes review, the court recognizes the vital need for an effective patent review process—one that promotes a competitive, affordable prescription drug market.”
Following MACRA
HHS this week unveiled plans to spend $100 million over the next 5 years to teach small physician practices how to follow the Medicare Access and CHIP Reauthorization Act, or MACRA, which calls for greater use of value-based reimbursement.
The difficulty that small practices have in embracing new payment models and understanding how to stay afloat financially under healthcare reform has concerned officials who do not want to lose practices that help rural or medically underserved areas. Groups that seek funding under the program must say how they will educate small practices without charging the groups or individual doctors. MACRA allows physicians to select quality care metrics that match the work they do in their practices, and this new program should help small practices select metrics that make the most sense.
Reimbursement, Quality
Aligning reimbursement with quality in cancer care is the theme of the new issue of Evidence-Based Oncology, which features commentary and coverage from recent meetings on value-based payment. The issue features:
Read the full issue of Evidence-Based Oncology.
For all of us at the Managed Markets News Network, I’m Justin Gallagher. Thanks for joining us.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
CMS released a final rule to help patients obtain Children’s Health Insurance Program (CHIP) coverage and issued a proposed rule to update Medicare payment policies and rates for inpatient rehabilitation facilities; debate over if gift card incentives are acceptable in health care marketing.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More